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Abstract
Introduction: The concept of the regulatory role of endothelium in the pathogenesis of pulmonary hypertension (PH) 
is fundamental.
Research objective: To study the protective effects of the selective arginase II inhibitors L207-0525 and L327-0346 in 
combination with tadalafil in a monocrotaline model of pulmonary hypertension in rats.
Materials and methods: Monocrotaline-induced pulmonary hypertension was simulated in 10 animals by a subcu-
taneous injection of an alcohol-water solution of monocrotaline (MCT) in the dose of 60 mg/kg. Seven days after the 
injection of MCT, the administration of L207-0525 and L327-0346 in the doses of 1 mg/kg and 3 mg/kg was started. 
The compounds were administered intragastrically once a day for 21 days.
Results and discussion: It was found that L207-0525 and L327-0346 in the dose of 3 mg/kg and tadalafil in the dose 
of 1 mg/kg prevented the development of pulmonary hypertension, which was expressed in a statistically significant 
decrease in the coefficient of endothelial dysfunction (CED, prevention of an increase in systolic pressure in the right 
ventricle, as well as Fulton, RV/BW and WT indices. The greatest activity was shown by L207-0525 and L327-0346 in 
the dose of 3 mg/kg in combination with tadalafil in the dose of 0.1 mg/kg.
Conclusions: The received results suggest the dose-dependent protective activity of selective arginase II inhibitors 
L207-0525 and L327-0346 and the development of the additive effect of their combined use with low doses of PDE-5 
inhibitor tadalafil in relation to the development of monocrotaline pulmonary hypertension.
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Introduction
Pulmonary arterial hypertension (PAH) is a group of li-
fe-threatening progressive diseases of various origins, 
characterized by a progressive increase in blood pressu-
re (BP) in the pulmonary artery (PA), remodeling of the 
pulmonary vessels, which leads to increased pulmonary 
vascular resistance and pulmonary arterial pressure, and, 
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as a result, to right ventricular heart failure and premature 
death. One of the important mechanisms of the pathoge-
nesis of PAH is the reduced formation of nitrogen oxide 
in endotheliocytes of pulmonary vessels (Félétou et al. 
2010, Machado and Gladwin 2005, Morris et al. 2008). 
Therefore, it is obvious that the PAH therapy should be 
aimed primarily at elimination of endothelial dysfunction, 
so in this regard, the attempts to restore the level of nitro-
gen oxide are pathogenetically justified.
In PH, the content of free NO and its derivatives de-
creases in whole blood, but increases in the tissues of the 
heart and lungs (Xu et al. 2004). The authors interpret 
these changes as a weakening of eNOS function and an 
increase in inflammation. At the same time, they record 
the presence of the signs of oxidative stress (an increase in 
ROS and a decrease in reduced glutathione in lungs) and 
suppose that this makes an additional contribution to a de-
crease in the level of free NO and its derivatives in blood. 
The modern literature confirms the influence of inflam-
mation on the development and progression of pulmonary 
hypertension (Munder et al. 2005). In addition, Th2, IL-
4, and IL-13 cytokines have been reported to induce the 
expression of arginase II in endothelial cells of the human 
pulmonary artery (Chang et al. 2000, Munder 2009).
Arginase is an enzyme that participates in the urea cy-
cle and is described in two isoforms: arginase I and ar-
ginase II. Arginase II is a mitochondrial enzyme which 
is expressed in several organs and tissues, including en-
dotheliocytes of pulmonary vessels. Arginase catalyzes 
the hydrolysis of L-arginine to L-ornithine and urea, and 
thus competes with NOS for a common substrate, L-argi-
nine. In accordance with the foregoing, in the endothelial 
layer, the competition between arginase II and eNOS re-
duces the bioavailability of NO, which leads to impaired 
vasodilation and, as a consequence, to endothelial dys-
function (Pernow and Jung 2013, Romero et al. 2008).
Materials and methods
The experiments were carried out in compliance with the 
requirements of the federal law of the Russian Federa-
tion On Protection of Animals Against Cruel Treatment 
dated June 24, 1998, the rules of laboratory practice in 
preclinical studies in the Russian Federation (GOST 3 
51000.3-96 and GOST R 53434-2009), European Com-
munity directives (86/609 EU), the rules and internatio-
nal recommendations of the European Convention for the 
Protection of Vertebrate Animals Used for Experimental 
and Other Scientific Purposes (1991).
The study was performed on 100 sexually mature Wistar 
male rats weighing 200–220 g. Seven days after the injec-
tion of MCT, the administration of selective arginase II in-
hibitors L207-0525 and L327-0346 in the doses of 1 mg/kg 
and 3 mg/kg, tadalafil in the dose of 10 mg/kg in monother-
apy and in the dose of 1 mg/kg in combination with L207-
0525 and L327-0346 was started; all the compounds were 
administered intragastrically once a day for 21 days. Thus, 
10 experimental groups were formed: 1 – intact animals; 2 
– control (MCT) (0.5 ml, 60% alcohol solution once subcu-
taneously); 3 – MCT + L207-0525 in the dose of 1 mg/kg; 
4 – MCT + L207-0525 in the dose of 3 mg/kg; 5 – MCT + 
L327-0346 in the dose of 1 mg/kg; 6 – MCT + L327-0346 
in the dose of 3 mg/kg; 7 – MCT + tadalafil in the dose of 
0.1 mg/kg; 8 – MCT + tadalafil in the dose of 1 mg/kg; 9 – 
MCT + L207-0525 in the dose of 3 mg/kg + tadalafil in the 
dose of 1 mg/kg; and 10 – MCT + L327-0346 in the dose 
of 3 mg/kg + tadalafil in the dose of 1 mg/kg.
Monocrotaline pulmonary hypertension was simulated 
by subcutaneous injection of an alcohol-water solution of 
МСТ in the dose of 60 mg/kg in the volume of 0.5 ml per 
animal (Kaminskii et al. 2011).
Seven days after MCT injection, the administration of 
the test compounds once a day for 21 days was started. 
Four weeks after the start of the experiment, the animals 
were anesthetized (chloral hydrate 150 mg/kg + zoletil 60 
mg/kg); the left carotid artery was catheterized to record 
blood pressure (BP), and the necessary pharmacological 
agents were bolus injected into the femoral vein. Systolic 
blood pressure (SBP), diastolic blood pressure (DBP) and 
heart rate (HR) were measured with the use of a Biopac 
hardware-software complex. In addition to the study of 
blood pressure, a number of functional tests were carried 
out with the subsequent assessment of changes in the pa-
rameters of systolic and diastolic blood pressure, as well as 
the heart rate in response to intravenous administration of 
the solution of acetylcholine (AC) in the dose of 40 μg/kg 
at 0.1 ml per 100g of animal body weight as well as chang-
es in hemodynamic parameters in response to intravenous 
administration of the solution of sodium nitroprusside 
(SN) in the dose of 30 μg/kg at 0.1 ml per 100g of animal 
body weight (Denisyuk et al. 2016, Ivlitskaya et al. 2016).
The level of development of endothelial dysfunction 
in the experimental animals, as well as a degree of its 
correction by the studied pharmaceutical substance, was 
estimated by the calculated coefficient of endothelial dys-
function (CED), calculated by the formula: CED = SBP 
SN/SBP AC, where SBP SN is the area of the triangle 
above the curve of blood pressure recovery in response to 
intravenous administration of sodium nitroprusside; SBP 
AC is the area of the triangle above the curve of blood 
pressure recovery in response to intravenous administra-
tion of AC (Korokin et al. 2009, Molchanova et al. 2016).
The hemodynamic parameters were determined with the 
use of the Biopac MP-150 system and AcqKnowledge 3.8.1 
software (USA). After measurement of hemodynamic pa-
rameters, the animal was withdrawn from the experiment; 
blood sample was drawn for analysis of the gas composition 
(partial pressure of oxygen and carbon dioxide) with the use 
of the Micro-Astrup apparatus (Denmark); then the heart 
was removed for weighing and estimating the absolute and 
relative mass of the right ventricle (Korokina et al. 2019)
After the physiological experiment, the pulmonary 
heart of animals was weighed as an indicator of the de-
velopment of hypertrophy, and histological preparations 
of the pulmonary vessels were made.
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The following parameters were used to reflect the de-
velopment of pulmonary hypertension:
• systolic pressure in the right ventricle (mm Hg);
• Fulton index – the ratio of right ventricular weight 
over left ventricular septal weight (%);
• RV/BW index (mg/g);
• wall thickness index of the pulmonary artery (%).
Results and discussion
Modelling of monocrotaline pulmonary hypertension sho-
wed that the animals after 4 weeks reduced body weight 
gain compared with the control.
The study of the histological pattern of MCT pulmonary 
hypertension discovered hyperplasia of the muscle layer of 
the pulmonary vasculature (Fig. 1). This makes it possible 
to conclude that on the 28th day of the simulation of MCT 
pulmonary hypertension, hypertrophy of the pulmonary 
artery vascular wall develops, which is confirmed by the 
results of the assessment of the functional indicators.
When assessing the results of MCT pulmonary hyperten-
sion in the animlas in the control group, there was a statis-
tically significant increase in blood pressure (BP) (Fig. 2).
L207-0525 and L327-0346 had a dose-dependent anti-
hypertensive effect expressed in a statistically significant 
decrease in blood pressure in the dose of 3 mg/kg, com-
pared with the MCT group (p <0.05) (Fig. 2).
L207-0525 and L327-0346 in the dose of 3 mg/kg in 
combination with tadalafil in the dose of 0.1 mg/kg re-
duced blood pressure indicators to a greater extent, pro-
viding an additional hypotensive effect (Fig. 2).
The results of the functional tests for endothelium-de-
pendent (AC 40 μg/kg iv) and endothelium-independent 
(nitroprusside 30 mg/kg iv) vessel dilatation, expressed in 
the calculated coefficient of endothelial dysfunction, are 
presented in Figure 3.
When assessing the protective activity of tadalafil in 
the doses of 0.1 mg/kg and 1 mg/kg, the CED values 
were 2.0±0.1 and 1.3±0.1, respectively. At the same time, 
the administration of the combination of the lower dose 
of tadalafil (0.1 mg/kg) with L207-0525 (3 mg/kg) and 
L327-0346 (3 mg/kg) showed better endothelioprotective 
activity than monotherapy of L207-0525 (3 mg/kg) and 
L327-0346 (3 mg/kg), where the CED indicators were 
1.2±0.1 and 1.1±0.1, respectively (Fig. 3).
L207-0525 and L327-0346 in the doses of 1 mg/kg and 
3 mg/kg intragastrically once a day showed a dose-de-
pendent protective activity, expressed in a significant de-
crease in CED (p<0.05) (Fig. 3).
At the same time, the statistically significant positive 
influence of L207-0525 (3 mg/kg) and L327-0346 (3 mg/
kg) in combination with tadalafil (0.1 mg/kg) was estab-
lished on the blood gas composition.
Direct measurement of pressure in the right ventricle 
showed that with the development of MCT pulmonary 
hypertension, systolic pressure in the right ventricle in-
creased to 41.3±2.3 mm Hg, while in the control series it 
was 23.0±1.2 mm Hg (р<0/05). At the same time, the Ful-
ton index increased from 23.5±1.2% to 32.1±1.3%, the 
RV/BW index from 0.6±0.02 mg/g to 0.8±0.02 mg/g, and 
the average wall thickness of the pulmonary artery – from 
0.18±0.01% to 0.23±0.01, respectively, when simulating 
MCT pulmonary hypertension. The influence of selective 
arginase II inhibitors L207-0525 and L327-0346, tadalafil 
on the development of pulmonary hypertension is pre-
sented in Table 2.
It was found that L207-0525 and L207-0525 in the 
doses of 1 and 3 mg/kg and tadalafil in the dose of 1 mg/
kg prevented the development of pulmonary hyperten-
sion, which was expressed in preventing an increase in 
systolic blood pressure in the right ventricle, Fulton, RV/
BW and WT indices. The greatest activity was shown by 
L207-0525 and L207-0525 in the dose of 3 mg/kg in com-
bination with tadalafil in the dose of 0.1 mg/kg.
Figure 1. Hyperplasia of the smooth muscle wall of the pulmonary artery (on the left – control; on the right – monocro-
taline pulmonary hypertension).
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The analysis of the relative weight of the heart found 
the expressed protective activity of L207-0525 and L327-
0346 in the dose of 3 mg/kg in combination with small 
doses of tadalafil of 0.1 mg/kg against the background of 
the simulation of monocrotalin-induced pulmonary hy-
pertension (Fig. 4).
Thus, the protective effect of new selective arginase 
II inhibitors L207-0525 and L327-0346 with respect to 
hypertrophy of the vascular wall of the pulmonary vascu-
lature was found when simulating monocrotaline pulmo-
nary hypertension.
Based on all the functional vascular and cardiac tests, 
the assessment of cardiodynamic effects on the model of 
MCT pulmonary hypertension, L207-0525 and L327-
0346 showed a dose-dependent protective activity. PDE-5 
tadalafil in the high dose of 1 mg/kg was slightly more 
effective than L207-0525 (3 mg/kg) and comparable in ef-
fectiveness with L327-0346 (3 mg/kg). The cardioprotec-
tive effects of the studied compounds involved preventing 
the development of pulmonary hypertension, a significant 
decrease in blood pressure and CED. In addition, L207-
0525 and L327-0346 in the dose of 3 mg/kg, tadalafil in 
the dose of 1 mg/kg prevented an increase in Fulton, RV/
BW and WT indices. The combination of L207-0525 and 
L327-0346 in the dose (3 mg/kg) once a day with tadalafil 
in a small dose (0.1 mg/kg) showed additive both endothe-
lial and cardioprotective effects on the model of MCT pul-
monary hypertension. Moreover, an increase in the dose 
of tadalafil to 1 mg/kg in the combination did not contrib-
ute to an improvement in all the studied parameters.
Therefore, the research results indicate the develop-
ment of the additive effect of the combined use of selec-
tive arginase II inhibitors L207-0525 and L327-0346 and 
small doses of PDE-5=Is in relation to the development of 
monocrotaline-induced pulmonary hypertension.
As is known, L-arginine is the only substrate for the 
synthesis of NO, which is actively biotransformed under 
the influence of the arginase II enzyme. The increased ac-
tivity of arginase II leads to a decrease in NO and, as a 
consequence, to the development of ED. According to a 
number of modern authors, the increased activity of argin-
ase enzymes is observed in various diseases, such as bron-
chial asthma, arthritis, glomerulonephritis, psoriasis, and 
diabetic erectile dysfunction. Inhibition of arginases con-
tributes to an increased production of nitrogen oxide and 
Figure 2. Indicators of systolic and diastolic blood pressure in the 
simulation of monocrotaline pulmonary hypertension and its cor-
rection by L207-0525 and L327-0346, tadalafil. Note: BP – blood 
pressure; DBP – diastolic blood pressure; SBP – systolic blood 
pressure, (MCT) – monocrotaline; *p <0.05 in comparison with 
the intact group, # – p <0.05 in comparison with the MCT group.
Figure 3. The influence of MCT on the coefficient of endothelial 
dysfunction and its correction by L207-0525 and L207-0525, 
tadalafil. Note: CED – coefficient of endothelial dysfunction, 
(MCT) – monocrotaline; * – p <0.05 in comparison with the 
intact group, # – p <0.05 in comparison with the MCT group.
Figure 4. Relative right ventricle weight (RVW) of the rats’ 
heart on the background of the simulation of MCT pulmonary 
hypertension and its correction by L207-0525 and L327-0346, 
tadalafil. Note: RVW – relative right ventricle weight; MCT – 
monocrotalin; * – p <0.05 in comparison with the intact group, 
# – p <0.05 in comparison with the MCT group.
Table 1. The Influence of L207-0525 and L327-0346, Tadalafil 
on the Parameters of the Blood Gas Composition on the Back-
ground of Modelling Monocrotaline Pulmonary Hypertension.
Experimental group
Partial pressure of 
oxygen PaO2  
(mm Hg)
Partial pressure 
of carbon dioxide 
PaCO2 (mmHg)
Intact 84.70±5.36 39.60±1.92
Control (MCT) 63.80±3.71* 52.50±1.27*
MCT + L207-0525 1 mg/kg 69.98±3.15# 48.13±2.78#
MCT + L207-0525 3 mg/kg 73.54±4.09# 45.07±1.35#
MCT + L327-0346 1 mg/kg 70.35±3.37# 46.90±1.86#
MCT + L327-0346 3 mg/kg 74.18±4.22# 44.36±2.49#
MCT + Tadalafil 0.1 mg/kg 70.67±3.88# 46.05±2.55#
MCT + Tadalafil 1 mg/kg 75.32±4.56# 44.07±2.09#
MCT + L207-0525 3 mg/kg 
+ Tadalafil 0.1 mg/kg
79.19±5.05# 43.71±2.11#
MCT + L327-0346 3 мг/кг 
+ Tadalafil 0.1 mg/kg
81.23±3.44# 42.45±2.04#
Note: MCT – monocrotaline; * – p <0.05 in comparison with the intact 
group, # – p <0.05 in comparison with the MCT group.
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the prevention of dysfunctional disorders in the endotheli-
um (Khong et al. 2012, Michell et al. 2011, Shemyakin et 
al. 2012, Yakushev et al. 2012, Yakushev and Pokrovsky 
2016). Therefore, the use of highly selective arginase II in-
hibitors is the most promising and pathogenetically reason-
able in the prevention and complex therapy of PH. As it is 
known, today there are no drugs from the group of highly 
selective arginase II inhibitors at the global pharmaceutical 
market. That is why the search for active candidate mol-
ecules, highly selective arginase II inhibitors, is justified.
It was determined that arginase II is expressed in en-
dothelial cells of the human pulmonary artery (Budhiraja 
et al. 2004). Therefore, it appears to be the main enzyme 
expressed in the pulmonary vasculature of humans and 
mice. Based on the analysis of the literature, it can be as-
sumed that arginase can contribute to the development of 
PH through several mechanisms. Firstly, arginases com-
pete with NOS for the mutual substrate, L-arginine, which 
leads to a decrease in the bioavailability of NO (Zuck-
erbraun et al. 2011). Secondly, end products of arginase 
enzymatic reactions include polyamines and L-proline. 
Polyamines are known to stimulate cell growth and dif-
ferentiation, and L-proline is an important component of 
collagen synthesis (Krystofova et al. 2018, Li et al. 2001). 
Thus, arginases can contribute to vascular remodeling by 
proliferation of vascular cells and expansion of the extra-
cellular matrix.
The modern literature confirms the influence of inflam-
mation on the development and progression of pulmonary 
hypertension (Chicoine et al. 2004). In experimental mod-
els of pulmonary hypertension, the increased presence and 
activity of inflammatory cells (including macrophages, pol-
ymorphonuclear neutrophils, lymphocytes and mast cells) 
is usually observed, which is accompanied by significant 
activation of inflammatory 16, 17 cytokines and growth 
factors (TNFα, IL-1β, IL-6, PDGFα, PDGFβ, TGFβ) and 
adhesion molecules. In addition, Th2, IL-4, and IL-13 cy-
tokines are reported to induce the expression of arginase 
I and arginase II in various cell types (Nelin et al. 2001).
Since arginase and NOS compete for their common 
substrate, L-arginine, an increased arginase activity can 
lead to a decrease in NO production, which contributes to 
vasoconstriction (Stanley KP et al. 2006). This concept is 
supported by the observation in a clinic where endothelial 
cells of pulmonary artery obtained from lungs of patients 
with PH had higher levels of arginase II protein and lower 
NO production than similar cells from lungs of patients 
without PH (Chicoine et al. 2004).
In addition to the treatment of erectile dysfunction, 
PDE-5-Is are widely used in clinical practice for the treat-
ment of both primary and secondary pulmonary hyperten-
sion. An important feature in the correction of PDE-5-IS 
is not only vasodilation, but also the prevention of re-
modelling vessels (Wang et al. 2018). The controlled ran-
domized trial revealed the presence of a vasorelaxating 
effect in conditions of pulmonary arterial hypertension in 
sildenafil, vardenafil, and tadalafil (Mokry et al. 2017)
Due to the accumulation of cGMP, PDE-5 inhibitors 
may have a stimulating influence on the metabolic path-
way of the formation of the nitrogen oxide NO/cGMP/
PDE. In addition, PDE-5-Is, due to the activation of K+ 
adenosine triphosphatase channels, can reduce the pro-
duction of VCAM and ICAM adhesion molecules and, 
therefore, prevent the activation of a endothelial dysfunc-
tion neutrophilic link; besides, PDE-5-Is in small doses 
probably activates protein kinase G, increasing at the 
same time the activity of eNOS and iNOS (Raina et al. 
2017, Schermuly et al. 2011, Zuckerbraun et al. 2011).
Thus, based on studies conducted, it can be assumed that 
selective arginase II inhibitors L207-0525, L327-0346, and 
PDE-5-I tadalafil exert the additive effects with the follow-
ing therapeutic targets involved: arginase II/NO bioavail-
ability and the cGMP/PDE-5 metabolic pathway (Fig.5).
Figure 5 presents the variants of the therapeutic influ-
ence of «L-arginine/NO/NOS» on NO synthesis through 
the classical pathway for the formation of nitrogen oxide, 
with «L-arginine/NO/NOS» through the accumulation of 
cGMP (cyclic guanosine monophosphate) stimulating 
the metabolic pathway «NO/cGMP/PDE-5». The first 
strategy is to increase the availability of the L-arginine 
substrate for NO synthesis using arginase inhibitors. Al-
ternative strategies involve the therapy that uses an ad-
vantage of cyclic-guanosine-monophosphate-dependent 
signaling, including type 5 phosphodiesterase inhibitors.
Table 2. The Influence of the Selective Arginase 2 Inhibitor L207-0525 and L327-0346, Tadalafil on the Development of Monocro-
taline-induced Pulmonary Hypertension (M±m; n=10).
Experimental series RVSP Fulton Index RV/BW Index WT Index
Intact animals 23.0±1.2 23.5±1.2 0.6±0.02 0.18±0.01
Monocrotaline 60 mg/kg (MCT) 41.3±2.3* 32.1±1.3* 0.8±0.02* 0.23±0.01*
MCT + L207-0525 1 mg/kg 36.4±1.9* 29.1±1.2* 0.7±0.02* 0.22±0.01*
MCT + L207-0525 3 mg/kg 27.1±1.8# 25.5±1.1# 0.6±0.02# 0.20±0.01#
MCT + L327-0346 1 mg/kg 35.2±1.6* 28.1±1.3* 0.7±0.01* 0.21±0.01*
MCT + L327-0346 3 mg/kg 26.7±1.7# 24.9±1.1# 0.6±0.02# 0.19±0.01#
MCT + Tadalafil 0.1 mg/kg 35.3±2.2# 26.4±1.3# 0.7±0.01# 0.21±0.01#
MCT + Tadalafil 1 mg/kg 32.5±2.1# 25.4±1.5# 0.7±0.02# 0.20±0.01#
MCT + L207-0525 3 mg/kg + Tadalafil 0.1 mg/kg 24.0±1.4# 24.5±1.3# 0.6±0.01# 0.18±0.01#
MCT + L327-0346 3 mg/kg + Tadalafil 0.1 mg/kg 23.0±1.2# 23.9±1.1# 0.6±0.02# 0.18±0.01#
Note: MCT – monocrotalin; RVSP – systolic blood pressure in the right ventricle (mm Hg); the Fulton index – weight ratio of the mass of the right 
ventricle/left ventricle and septum (%); RV/BW – index ventricular weight (mg/g); WT index – the pulmonary artery wall thickness (%). * – p 
<0.005 compared to control; # – p <0.005 compared to MCT.
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Summarizing the foregoing, a further experimental and 
then clinical study of the combined effects of selective 
arginase II inhibitors L207-0525, L327-0346 and small 
doses of the PDE-5 inhibitor tadalafil aimed at improve-
ment of the treatment of pulmonary arterial hypertension 
appears to be necessary.
Conclusions
1. The results indicate the dose-dependent protective 
activity of selective arginase II inhibitors L207-
0525 and L327-0346 in relation to the development 
of monocrotalin pulmonary hypertension.
2. Further studies of protective activity on the PH 
model will objectively assess the prospects for the 
use of new selective arginase inhibitors L207-0525 
and L327-0346 in the treatment of PH.
3. The combination of selective arginase II inhibitors 
L207-0525 and L327-0346 in the dose of 3 mg/kg 
with tadalafil in a small dose of 0.1 mg/kg once a day 
intragastrically for 21 days at monocrotaline pulmo-
nary hypertension showed the highest additive effect.
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